These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37917373)

  • 21. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
    Yakymiv Y; Augeri S; Bracci C; Marchisio S; Aydin S; D'Ardia S; Massaia M; Ferrero E; Ortolan E; Funaro A
    Sci Rep; 2021 Oct; 11(1):21230. PubMed ID: 34707185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
    Brunner AM; Blonquist TM; DeAngelo DJ; McMasters M; Fell G; Hermance NM; Winer ES; Lindsley RC; Hobbs GS; Amrein PC; Hock HR; Steensma DP; Garcia JS; Luskin MR; Stone RM; Ballen KK; Rosenblatt J; Avigan D; Nahas MR; Mendez LM; McAfee SL; Moran JA; Bergeron M; Foster J; Bertoli C; Manning AL; McGregor KL; Fishman KM; Kuo FC; Baltay MT; Macrae M; Burke M; Behnan T; Wey MC; Som TT; Ramos AY; Rae J; Lombardi Story J; Nelson N; Logan E; Connolly C; Neuberg DS; Chen YB; Graubert TA; Fathi AT
    Lancet Haematol; 2020 Feb; 7(2):e122-e133. PubMed ID: 31837959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
    Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
    J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
    Yang J; Weisberg EL; Liu X; Magin RS; Chan WC; Hu B; Schauer NJ; Zhang S; Lamberto I; Doherty L; Meng C; Sattler M; Cabal-Hierro L; Winer E; Stone R; Marto JA; Griffin JD; Buhrlage SJ
    Leukemia; 2022 Jan; 36(1):210-220. PubMed ID: 34326465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
    Chromik J; Safferthal C; Serve H; Fulda S
    Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).
    Garrido SM; Appelbaum FR; Willman CL; Banker DE
    Exp Hematol; 2001 Apr; 29(4):448-57. PubMed ID: 11301185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
    Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
    Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
    Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
    Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Fu JF; Shih LY; Yen TH
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.
    Heasman SA; Zaitseva L; Bowles KM; Rushworth SA; Macewan DJ
    Oncotarget; 2011 Sep; 2(9):658-68. PubMed ID: 21911919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytarabine-induced TNFα promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukaemia.
    Bai H; Peng Y; Li Y; Duan J; Fu W; Liang X; Yu W; Zhang Q
    Scand J Immunol; 2022 Jun; 95(6):e13158. PubMed ID: 35285047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.